CAN1012 Injections for Cancer

Recruiting at2 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: CanWell Pharma Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests CAN1012, a drug that activates the immune system, in patients with advanced cancer who can't use standard treatments. The drug works by stimulating the immune system to fight cancer cells.

Research Team

Eligibility Criteria

This trial is for adults over 18 with advanced solid tumors that have worsened or don't respond to standard treatments. They must not be pregnant, agree to use contraception, and have good organ function. People with bleeding disorders, certain mental health issues, active infections including HIV, recent investigational drug use, or those on systemic steroids can't join.

Inclusion Criteria

My blood tests and kidney function are within the required ranges, and I can care for myself.

I am a man who can father children and will use birth control during and 120 days after the study.

Women who could become pregnant must have a negative pregnancy test within 3 days before starting the study drug.

Exclusion Criteria

I have an active HIV infection.

I am currently being treated for an infection.

I am not taking drugs that are highly affected by liver enzymes.

Treatment Details

Interventions

• CAN1012 (Monoclonal Antibodies)

Trial Overview The study tests CAN1012 (a Selective TLR7 Agonist) given by injection directly into the tumor in patients who lack effective standard therapy options. It aims to assess its safety and how well it works against various solid tumors.

Participant Groups

Group I: CAN1012 single agent Experimental Treatment 1 Intervention

CAN1012 intratumoral injection given alone

Who Is Running the Clinical Trial?

CanWell Pharma Inc.

Lead Sponsor

Trials

1

Recruited

40+